AT homozygotes have a 100-fold higher risk of cancer than the general population (Swift et al., 1991) thus it is possible that defective p53 induction is a key factor in their cancer predisposition. In the present study, we have extended the previous work to examine p53 induction in AT heterozygotes. These comprise about 1-3% of the general population and epidemiological studies suggest that they also have a significantly increased risk of cancer (Peterson et al., 1992 The AT cells were obtained from Professor Martin Lavin. Peripheral blood samples were obtained from normal female donors and from breast cancer patients at least 6 months after radiotherapy treatment at the Queensland Radium Institute. The 27 breast cancer patient LCLs included five from patients who had experinced severe late effects from clinical radiotherapy. These were included to examine correlation between in vitro p53 induction and clinical radiosensitivity.
Exposure of mammalian cells to 7-radiation results in an inhibition of replicative DNA synthesis and cell cycle arrest.
The arrest of cells in GI phase is accompanied by a concurrent increase in stable p53 protein. Cells that either lack p53 gene expression or overexpress a mutant form of p53 do not exhibit a GI arret after 7-radiation (Kastan et al., 1991) . Kuerbitz et al. (1992) demonstrated that expression of wildtype p53 causes the GI arrest after 7-radiation by (1) acquisition of the GI arrest following transfection of wild-type p53 genes into p53-deficient cells and (2) loss of the GI arrest following transfection of mutant p53 genes into cells with wild-type p53 genes. Cell cycle checkpoints presumably exist to prevent replication of a damaged DNA template (GI arrest) and segregation of damaged chromosomes (G2 arrest Kastan et al., 1992) . Delays at these checkpoints presumably allow DNA repair before replicative DNA synthesis and mitosis so that cellular survival is enhanced and the transmission of genetic errors reduced (Weinert and HartwelL 1988) .
As well as cell cycle regulation, p53 has been implicated in apoptosis, probably by means of transcriptional regulation (Lane, 1994) . Studies on human tumour cell lines expressing mutant p53 have shown increased resistance to 7-radiation (Mcllwrath et al., 1994 ) when compared with lines expressng wild-type p53. They postulate that resistance may result from the inability of the cells to undergo apoptosis. However, others have failed to observe a correlation with p53 status and radiosensitivity (Brachman et al., 1993) .
Ataxia telangiectasia (AT) is a human autosomal recessive disorder characterised by chromosomal instability, extreme sensitivity to 7-radiation and a predisposition to cancer. Cells from AT homozygotes show a reduced induction in p53 protein post 7-radiation compared with normal donor cells (Kastan et al., 1992; Nasrin et al., 1994) . Also, AT cells are deficient in the GI arrest post radiation (Nagasawa and Little, 1983) and demonstrate radioresistant DNA synthesis (Houldsworth and Lavin, 1980) . Lavin et al. (1992) showed that AT heterozygotes can be identified by a greaer than normal accumulation of LCLs in G2 phase 24 h post irradiation using a fluorescence-activated cell analyser. This phase delay was not observed in the G1 phase where the p53 protein is involved. We set out to measure p53 induction in LCLs from breast cancer patients and to examine correlation with cellular radiosensitivity.
LCLs from AT homozygotes show a deficient p53 induction in response to 7-radiation yet a normal response to UVB radiation, an agent to which AT cells are not hypersensitive (Khanna and Lavin, 1993) . Nasrin et al. (1994) AT homozygotes have a 100-fold higher risk of cancer than the general population (Swift et al., 1991) thus it is possible that defective p53 induction is a key factor in their cancer predisposition. In the present study, we have extended the previous work to examine p53 induction in AT heterozygotes. These comprise about 1-3% of the general population and epidemiological studies suggest that they also have a significantly increased risk of cancer (Peterson et al., 1992) . In partiular, females have been shown to have a 6.8-fold increased risk of developing breast cancer (Swift et al., 1990 (Neitzel, 1986 
MIT assay of cell killing
The MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium)-based colorimetric growth assay (Mossman, 1983) was used for the estimation of cellular radiosensitivity and is described in detail elswhere (Ramsay and Birrel, 1995) . Briefly, confluent, viable cells are irradiated to various doses (0, 0.5, 1 and 2 Gy) and plated into quadruplicate wells of replcate 96-well microplates. After 5 and 7 days post irradiation, the MTT reagent is added at 500 iLg ml-' and the microplates reincubated for 4 h to allow mitochondrial enzymes to reduce the MTI to a coloured insoluble formazan product. After formazan solubilisation in dimethyl sulphoxide (DMSO) the microplates are analysed using a multi-well spectrophotometer and surviving fractions calculated.
Statistical analysis Analysis of statistical significance was determined using Student's two-tailed t-test. Confidence limits of 95% were determined using Sigmaplot Scientific Graphing Software (Jandel, CA, USA).
Clinical information
Records of individuals with breast cancer were examined for age, family history of cancer and adverse reaction to radiotherapy. They were assessed on the Radiation Therapy Oncology Group (RTOG) scoring scheme for late effects (Ramsay and Birrell, 1995) .
Resdts
Time, dose and linearity of response A preliminary experiment of the effect of cell growth on radiation-induced p53 protein expression showed an approximately 2-fold higher induction in irradiated cells from an exponential culture when compared with irradiated cells from a stationary phase culture of the same normal donor LCL (Table I) . Exponential cultures were used throughout this study.
Preliminary assays of time and dose response to radiation treatment were performed on a normal donor LCL and AT LCLs. In the dose response, the normal LCL showed maximal p53 induction after 8 Gy while the AT line showed a much lower response. In the time course experiments, the normal donor showed a rapid induction up to 5 h then a fall-off down to basal levels by 24 h. For the AT LCLs, there was a small increase in p53 in groups A and D which again fell off by 24h. One AT LCL (group E) showed a siilar increase in p53 levels to the normal but the response was delayed (Figure lb significantly different from the normal donors (P = 0.4), but 5/27 (18%) had relatively low levels of p53 induction which was in the AT heterozygote range (95% confidence limits). For the normal donor LCLs, only 1/17 (6%) was within the AT range.
Relationship to radiosensitivity We have previously reported on variations in radiosensitivity in LCLs derived from breast cancer patients using the MTT assay (Ramsay and Birrell, 1995) . Patients who developed complications from radiotherapy were found to be significanty more sensitive. Direct comparison was made between radiosensitivity as measured by surviving fraction at 2 Gy and levels of p53 induction in the 27 assessable breast cancer patients. The data are plotted in Figure 4 and there is no correlation between the two parameters. Relationship to clinicalfactors Late reaction to clinical radiotherapy was assessed using the RTOG scoring scheme in 17 of the 27 breast cancer patients at least 2 years after radiotherapy for primary breast cancer. Five of these individuals were judged to have suffered severe late reactions (Grade 3 or 4) to skin and subcutaneous tissue in the irradiated area. Two of the five showed a markedly deficient response (levels 0.15 and 0.30) but the remaining three showed p53 induction within the normal range. Similarly, the three other individuals with low p53 induction showed normal response to radiotherapy. This data would suggest that this assay would have a low probability of predicting clinical radiosensitivity. Four of the breast cancer patient LCLs were from individuals with family histories of cancer. All four had basal p53 levels within the normal range and showed a p53 response to 7-radiation also within the normal range. No correlation was observed between patient age and p53 induction (data not shown).
Dission
The -tradiation-induced and basal levels of p53 protein in 57 lymphoblastoid cell lines were assessed using Western blotting with scanning densitometry. LCLs from AT homozygotes show a deficient p53 induction in response to 7-radiation yet a normal response to UVB radiation, an agent to which AT cells are not hypersensitive (Khanna and Lavin, 1993) . Nelson and Kastan (1994) to an increased proportion of AT heterozygotes reported to occur in the breast cancer population (Easton, 1994) . Epidemiological studies have suggested that between 5% and 18% of all breast cancer patients may be AT beterozygotes (Swift et al., 1991; Swift, 1994) , although confirmation will have to await the cloning of the AT gene(s). In view of the importance of p53 in tumorigenesis, it is possible that induced levels of p53 may be seen in other cancer-prone genetic disorders.
Other methods have been used to identify AT heterozygotes, including assays of cellular radiosensitivity (Chen et al., 1978; Weeks et al., 1991) , cytogenetic analysis (Parshad et al., 1985) and assays of cell cycle anomalie post irradiation (Lavin et al., 1992; Peterson et al., 1992) . In the study by Weeks et al. (1991) , the colony-forming ability after low-dose-rate irradiation was measured in fibroblasts from AT homozygotes, AT heterozygotes and normal donors. They conclude that overlap in values between AT heterozygotes and normls precludes the use of the assay for the accurate identification of heterozygotes. Similarly, in the present study we observed a significnt difference in p53 protein induction between these two groups but overlap precludes the use of the assay for AT heterozygote identification. Parshad et al. (1985) found that fibroblasts from AT heterozygotes, ike AT homozygotes, show a significntly higher frequency of chromatid breaks and gaps than normal controls using doses up to 1 Gy. Flow cytometric cell cycle analysis of AT LCLs has demonstrated a higher than normal accumulation of cells in G2 phase, 24 h after 3 Gy -tradiation (Lavin et al., 1992 induction post ?-radiation to examine for correlation between the two parameters. Scott et al. (1994) used an assay of radiation-induced chromosome damage in lymphocytes in an attempt to identify AT heterozygotes in women with breast cancer. The assay was a modification of that described by Sandford and Parshad (1990) who show that sensitivity to radiationinduced chromosome damag in G2 cells is strongly associated with inherited cancer predisposition. In a series of 50 patients 21 (42%) had a chromosomal radiosensitivity in the AT heterozygote range compared with 7/74 (9%) of control donors. These values are higher than those esimated for AT heterozygotes in either group (Easton, 1994) . SV40 transformation of human skin fibroblasts has been shown to cause an increase in -radiation rsstance and increased production of p53 mRNA when compared with primary cell cultures (Luckehuhle, 1994) . We have no evidence for similar changes to lymphoid cells when transformed with EBV. Mitogen-stimulated peripheral blood lymphocytes will grow and divide in cell culture for several passages only. EBV-transformed lymphocytes will grow indefinitely in culture but may undergo genetic changes after extended periods in culture. Thus we endeavoured to use early passage number LCLs and ensured the LCLs had diploid DNA content by using flow cytometry of propidium iodide-stained cultures (data not shown).
In summary, the Western blot assay described here demonstrates significant differences in the -tradiation-induced p53 response between normal donors, AT heterozygotes and AT 
